611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
New Cancer Drug Shows Promise Against Wide Range of TumorsFirefighters May Face Higher Odds for Skin CancerMany With Early Breast Cancer Are Skipping ChemoWoman's Selfie of Skin Cancer Went Viral, Sparked AwarenessASH: Daratumumab Aids Newly Diagnosed Multiple MyelomaArtificial Intelligence Promising for CA, Retinopathy DiagnosesPediatric Oncologists Willing to Consider Medical MarijuanaGet Active, Beat Lymphoma?SABCS: 3D Mammography Could Help Rein in Screening CostsOvarian CA Screening Potentially Cost-Effective in the U.S.Just a Little Weight Loss May Cut Breast Cancer RiskFor Breast Cancer Patients, Less Time on Hormonal Meds?Acupuncture May Ease Pain Tied to Breast Cancer CareSABCS: Ribociclib Ups PFS in HR+ HER2− Advanced Breast CancerBirth Control Pill Tied to Slight Rise in Breast Cancer RiskDoctors' Personal Experience of Breast Cancer May Impact CareNew Breast Cancer Drug May Benefit Younger Women, TooLymph Node Density Predicts Thyroid Cancer OutcomesInsurance Ups the Odds of Beating CancerOral Microbiome Composition Linked to Esophageal Cancer RiskHealth Tip: Understanding Family Cancer SyndromeFDA Approves Biosimilar Ogivri for Breast, Stomach CancersDifferences in Cancer Survival by Type of Insurance>40% of Cancers, Cancer Deaths Due to Modifiable Risk FactorsFDA Approves 'Biosimilar' Drug Ogivri for Breast, Stomach CancersGum Disease Tied to Yet Another Deadly Illness5 Things You Should Know About Cervical CancerLess Frequent Biopsy May Be Option in Prostate Cancer CareSex, Race, Age Disparities in Survival for HPV-Linked Cancer6 Percent of Cancers Caused by Excess Weight, DiabetesHistory of Prior Cancer Common in Newly Diagnosed PatientsMemo to Doctors: Spit Out the Bad News1 in 4 U.S. Seniors With Cancer Has Had It BeforeStool-Based Protein Combos Can Improve CRC ScreeningNAFLD Linked to Increased Cancer Incidence RateCancer Survivors Can Develop PTSD, TooDrug Combo Doesn't Lengthen Glioblastoma SurvivalHealth Tip: Talking With Your Child's Cancer-Care TeamER- Breast CA Risk Up for African-Americans With T2DMHow to Do a Skin Cancer Body CheckStudy Untangles Disparity in Colon Cancer Survival RatesDiabetes May Be Driving High Rates of Breast Cancer in Black WomenOral Chemotherapy Parity Laws Offer Some Financial ProtectionHealth Tip: Recognize Symptoms of Oral CancerBreast Cancer Recurrences Steady After Therapy CessationLow-Fat Diet May Cut Pancreatic Cancer Risk for Overweight Older WomenKnow the Signs of Ovarian Cancer and Your RisksHealth Tip: Accept Help if Your Child Has CancerAverage Cost of Care in Year After Ovarian Cancer Surgery ~$100KRisk of Breast Cancer's Return Can Linger for Decades
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Blood Test May Spot Lung Cancer's Return, Even Before Scans

HealthDay News
by -- Robert Preidt
Updated: Mar 20th 2017

new article illustration

MONDAY, March 20, 2017 (HealthDay News) -- A blood test can detect the return of lung cancer months before CT and PET scans, a new study suggests.

The research included 48 adults with stage 2 or 3 locally advanced non-small cell lung cancer (NSCLC). The patients were aged 31 to 84. All were treated with chemotherapy and radiation.

Blood samples were taken before treatment, during treatment, and at six different times during the two years following treatment. The blood samples were checked for increased levels of circulating tumor cells, the researchers said.

The blood tests were able to detect lung cancer recurrence an average of six months before CT and PET scans, the investigators found.

The study was presented March 16 at a meeting of the American Society for Radiation Oncology, in San Francisco. Research presented at meetings should be viewed as preliminary until published in a peer-reviewed journal.

"The additional lead time afforded by an earlier diagnosis may enable doctors to better tailor alternative and salvage treatments to improve their patients' outcomes and quality of life," said lead author Chimbu Chinniah. He is a research fellow in radiation oncology at the University of Pennsylvania School of Medicine in Philadelphia.

"Earlier detection of recurrence may even translate into an increased likelihood of curing these patients when their tumor burden is lowest and thus more likely to respond to therapy," Chinniah suggested in a society news release.

According to the study's senior author, Dr. Charles Simone II, "The future use of circulating tumor cells as a diagnostic and prognostic tool for localized NSCLC looks promising."

Simone said that imaging tests -- such as CT and PET scans -- will remain "the cornerstone of post-treatment surveillance."

But blood tests could be used together with imaging scans. This combination might be a better way to monitor patients after treatment, he added. Simone is an associate professor of radiation oncology at the University of Maryland School of Medicine, in Baltimore.

More information

The U.S. National Cancer Institute has more on lung cancer.